Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $40.00 price target on Summit Therapeutics plc (NASDAQ: SMMT).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments